Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.

Overview

A Phase 1, Open Label, Parallel-Cohort, Randomized, Fixed Sequence Study To Evaluate The Pharmacokinetic Drug Drug Interaction Between PF-04965842 and Fkuvoxamine (cohort 1) or Fluconazole (Cohort 2) in healthy subjects.

Full Title of Study: “A PHASE 1, OPEN-LABEL, RANDOMIZED, FIXED-SEQUENCE, PARALLEL-COHORT STUDY TO ESTIMATE THE EFFECT OF FLUVOXAMINE OR FLUCONAZOLE, ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A SINGLE DOSE OF PF-04965842 IN HEALTHY SUBJECTS”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 13, 2018

Detailed Description

A phase 1 study to evaluate the effect of fluvoxamine (a strong CYP2C19 and moderate CYP3A inhibitor) or fluconazole (a strong CYP2C19, moderate CYP2C9 and CYP3A inhibitor) on the pharmacokinetics, safety and tolerability of PF-04965842 in healthy subjects. This study will be a Phase 1, open label, randomized, fixed-sequence, parallel-cohort study drug-drug interaction study. The study includes 2 periods: In Period 1: all subjects will receive one single oral dose of 100 mg PF 04965842 tablet. (Treatment A). PK will be evaluated in the first 72 hours post adminstration of PF 04965842. In Period 2: – Cohort 1: subjects will receive fluvoxamine (immediate release tablet 50 mg) once daily for 9 consecutive days; on Day 8, subjects will receive a single oral dose of 100 mg PF 04965842 approximately 3 hours after fluvoxamine administration. (Treatment B). PK will be evaluated in the first 72 hours post administration of PF 04965842. – Cohort 2: subjects will receive fluconazole capsule(s) once daily for 7 consecutive days (400 mg on Day 1 and 200 mg on Day 2-7 in Period 2); on Day 5, subjects will receive a single oral dose of 100 mg PF 04965842 approximately 1 hour after fluconazole administration. (Treatment C). PK will be evaluated in the first 72 hours post administration of PF 04965842.

Interventions

  • Drug: Period 1 – Day 1: PF-04965842 administered
    • Period 1: Single administration of 100 mg PF 04965842.
  • Drug: Period 2: Cohort 1: Fluvoxamine & PF-04965842
    • Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
  • Drug: Period 2: Cohort 2: Fluconazole & PF-04965842
    • Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.

Arms, Groups and Cohorts

  • Experimental: PF-04965842
    • investigational drug

Clinical Trial Outcome Measures

Primary Measures

  • Plasma Cmax for PF 04965842
    • Time Frame: First 72 hours post PF-04965842 administration in Period 1 and Period 2
    • Maximum Observed Plasma Concentration (Cmax) for PF 04965842
  • AUCinf for PF-04965842
    • Time Frame: First 72 hours post PF-04965842 administration in Period 1 and Period 2
    • Area Under the Curve From Time Zero to Extrapolated Infinite Time for PF 04965842 (AUCinf)

Secondary Measures

  • Number of subjects with Adverse events (AEs)
    • Time Frame: Screening up to 28 Days after the Last Dose of PF 04965842
    • Number of subjects with Adverse events (AEs)
  • Number of subjects with laboratory tests findings of potential clinical importance
    • Time Frame: Screening up to 7-14 Days after the Last Dose of PF 04965842 in Period 2
    • Number of subjects with laboratory tests findings of potential clinical importance
  • Number of Subjects with clinically significant abnormal Vital Signs
    • Time Frame: Screening up to 7-14 Days after the Last Dose of PF 04965842 in Period 2
    • Number of Subjects with clinically significant abnormal Vital Signs
  • Number of Subjects with Electrocardiograms (ECGs) findings of potential clinical importance
    • Time Frame: Screening up to 7-14 Days after the Last Dose of PF 04965842 in Period 2
    • Number of Subjects with Electrocardiograms (ECGs) findings of potential clinical importance

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy male or female subjects. – Body mass index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight >50 kg (110 lb). Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease. – Evidence or history of clinically significant dermatological condition (eg, contact dermatitis or psoriasis) or visible rash present during physical examination. – History of hypersensitivity to or intolerance of fluvoxamine and/or fluconazole. – Any condition possibly affecting drug absorption. – A positive urine drug test. – Screening supine systolic BP <90 mm Hg or 140 mm Hg following at least 5 minutes of supine rest OR Screening supine diastolic BP <50 mm Hg or 90 mm Hg following at least 5 minutes of supine rest. – Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Pfizer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pfizer CT.gov Call Center, Study Director, Pfizer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.